GSK620 is a potent orally bioactive pan-BD2 inhibitor (antagonist) with good broad spectrum (a wide range) selectivity, developability and in vivo oral pharmacokinetics, and is selective for BET-BD2 family proteins, exceeding all other BETs bromodomains 200 times more. GSK620 displays an anti~inflammatory phenotype in human whole blood.

Physicochemical Properties

Molecular Formula	C18H19N3O3
Molecular Weight	325.3618
Exact Mass	325.14
Elemental Analysis	C, 66.45; H, 5.89; N, 12.91; O, 14.75
CAS #	2088410-46-0
PubChem CID	126648559
Appearance	White to off-white solid powder
LogP	1.5
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	5
Heavy Atom Count	24
Complexity	599
Defined Atom Stereocenter Count	0
InChi Key	QZZCUOVXHPAQRQ-UHFFFAOYSA-N
InChi Code	InChI=1S/C18H19N3O3/c1-19-17(23)15-9-13(16(22)20-14-7-8-14)11-21(18(15)24)10-12-5-3-2-4-6-12/h2-6,9,11,14H,7-8,10H2,1H3,(H,19,23)(H,20,22)
Chemical Name	1-Benzyl-N5-cyclopropyl-N3-methyl-2-oxo-1,2-dihydropyridine-3,5-dicarboxamide
Synonyms	GSK-620 GSK620 GSK 620
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	In whole human blood, GSK620 has an anti-inflammatory characteristic. LPS was used to induce a robust immunological response in human blood samples. monocyte chemoattractant protein 1 (MCP-1/CCL2) measurement. This chemokine draws dendritic cells, memory T cells, and monocytes to vital areas. At dosages suspected to restore (expected) ~1 log efficacy relative to observed biochemical BRD4 BD2 efficacy, GSK620 decreases MCP-1 responses [1].
ln Vivo	Treatment was seen in various models of induced diabetes, psoriasis, and arthritis, highlighting the value of GSK620 as a household tool [1].
References	[1]. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. J Med Chem. 2020;63(17):9093-9126.

Solubility Data

Solubility (In Vitro)

DMSO : ~62.5 mg/mL (~192.09 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (6.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.0735 mL	15.3676 mL	30.7352 mL
	5 mM	0.6147 mL	3.0735 mL	6.1470 mL
	10 mM	0.3074 mL	1.5368 mL	3.0735 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.